Arcus Biosciences, Inc. — Form 8-K
Filed October 23, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 44/100
What the filing says
Arcus Biosciences sold 14,285,715 shares at $17.50/share to a syndicate led by Jefferies, Leerink Partners, and TD Securities, raising approximately $250M gross proceeds (or ~$235M net). The company granted underwriters an option to purchase an additional 2,142,857 shares within 30 days. Thirteen company insiders including CEO Robert Goeltz agreed to 60-day lock-ups. Closing occurred October 23, 2026.
Why this rating
Moderate dilutive capital raise (~4.3% of shares outstanding before option exercise, ~$235M net proceeds vs. $566M market cap). Typical biotech financing; expands runway but at modest relative scale for company size.
See more from October 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.